Clinical Trials
577 trials99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors
Nanjing First Hospital, Nanjing Medical University
INSPIRE
Singlera Genomics Inc.
In This Study, a Retrospective Analysis Was Conducted to Explore the Risk Factors for Patients Undergoing Pancreaticoduodenal Surgery (PD) to Achieve TO, and a Nomogram Prediction Model Was Further Established to Promote the Standardization and Standardization of PD Surgical Quality Evaluation.
Changzhou No.2 People's Hospital
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
ASCEND
Australasian Gastro-Intestinal Trials Group
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results
Suzhou Genhouse Bio Co., Ltd.
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
A Study of HY-0102 in Patients With Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
The Effect of Probiotics ATG-F4 in Cancer Patients
Chungnam National University Hospital
U87 CART in Treatment of Advanced Solid Tumor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
PCEDP
White Plains Hospital
Nab-PIPAC
University Hospital, Geneva
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Air Force Military Medical University, China
Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis
Changhai Hospital
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
MIRCA & MIPAC
Radboud University Medical Center
PRIORITY-CONNECT 2 Pilot Trial
Surgical Outcomes Research Centre (SOuRCe)
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen Inc.
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
Seoul National University Hospital
NaliCap
Seoul National University Hospital
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
C3
State University of New York - Downstate Medical Center
EDEN
GCS Ramsay Santé pour l'Enseignement et la Recherche
QPCS
McGill University Health Centre/Research Institute of the McGill University Health Centre
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
Gangnam Severance Hospital
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Beijing Friendship Hospital
BESTDRAIN
Radboud University Medical Center
REMBRANDT
Radboud University Medical Center
EUS-CTC
Institut Paoli-Calmettes
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
Yonsei University
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
MIKE-1
Nagoya University
PANORAMA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
1Globe Biomedical Co., Ltd.
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RenJi Hospital
ONFM-SBRT
Peking University Third Hospital
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
IMAGene
European Institute of Oncology
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Pancreatic Cancer & Surgical Resection
Methodist Health System
AiPPEAR
University Medical Center Goettingen
Combined Exercise and Nutritional Intervention in GI Cancer Patients
Hospital Beatriz Ângelo
Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis
The Affiliated Hospital of Qingdao University
VANISSh
IRCCS San Raffaele
CAOS
IRCCS San Raffaele